← Sticker Wall MODEL · DETAIL

Joint Development and Licensing of Private AI Models for Biomedical Research

1) Custom Development: Charging pharmaceutical companies project-based fees for model customization; 2) Licensing: Annua

MODEL

Key Fields

FIELD STAMPS

IndustryHealthcare / Elderly Care

RegionMulti-region

ScaleMid-size

ChannelHybrid

📌 Background

Leveraging MIT CSAIL's liquid neural network technology, Liquid AI provides a lightweight, high-efficiency model foundation, deeply integrated with biomedical companies. In July 2026, the company entered into a strategic partnership with Insilico Medicine to launch specialized, low-cost, on-premise research AI models for pharmaceutical firms. This solution compresses traditional models that previously required GPU clusters into a low-cost deployment format, meeting the data compliance and privatization needs of pharmaceutical companies.

👤 Target Customers

Large pharmaceutical companies, biotech firms, and CROs that require private AI model deployment and data residency solutions.

💰 Revenue Streams

1) Custom Development: Charging pharmaceutical companies project-based fees for model customization; 2) Licensing: Annual fees for private model usage; 3) Maintenance Subscription: Annual subscription fees for version updates and operational support; 4) Scalable Replication: Replicating joint development models for additional pharmaceutical companies and CROs (Opportunity: Revenue potential from scaling to more clients is currently unquantified).

🧮 Cost Structure

R&D investment in industry-specific fine-tuning and training delivery, labor and computing costs for joint development with biomedical partners, and expenses for sales and pre-sales solution support.

🛡️ Moat

The alignment between low-compute liquid neural network deployment and the strict compliance requirements of the biomedical sector, exclusive partnerships with industry leaders like Insilico Medicine, and the accumulation of industry-specific datasets and fine-tuning expertise.

🔑 Keys to Success

Secure 3-5 flagship cases with top pharmaceutical firms to create an industry replication effect.
Continuously accumulate industry-specific fine-tuning data for scenarios such as drug discovery and preclinical research.
Establish a compliance dialogue mechanism with regulatory bodies regarding AI-assisted research.

⚠️ Risks

High concentration of clients in a single industry, where order volatility could impact revenue stability.
The performance of liquid neural networks in modeling complex biological sequences requires further large-scale validation.

🏢 Cases

Liquid AI and Insilico Medicine partnered to launch a specialized on-premise research AI model for pharmaceutical companies.
Joint development of a specialized AI foundation model for longevity science with Human Longevity.

📊 SWOT Analysis

Strengths

Low-compute deployment significantly lowers the barrier to entry for AI adoption in pharma, while private deployment ensures data compliance.
Strategic partnerships with top-tier biomedical firms provide validation and endorsement for vertical scenarios.

Weaknesses

The biomedical industry still primarily favors cloud-based large models, leading to high customer education costs.
Model interpretability and regulatory approval pathways remain unclear.

Opportunities

The medical AI market is growing steadily, with private deployment becoming a necessity for pharmaceutical companies.
Emerging research fields such as longevity science and multi-omics are driving demand for specialized models.

Threats

Competition from industry giants like NVIDIA, which are launching medical-specific models and solutions.
Open-source biomedical large models are lowering the technical barrier to entry for the industry.

Sources